Showing results (221-230 of 242) with videos related to

Sort By:
Pageof 25
Oncotarget|February 5, 2017
Claudin-3 expression increases the malignant potential of lung adenocarcinoma cells: role of epidermal growth factor receptor activationLianmin Zhang, Yuan Wang, Bin Zhang, et al.
International Journal of Cancer|May 4, 2023
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLCShengxiang Ren, Jifeng Feng, Shenglin Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung CancerMark M Awad, Patrick M Forde, Nicolas Girard, et al.
Plos One|July 2, 2015
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell CarcinomasDongsheng Yue, Hui Li, Juanjuan Che, et al.
The Lancet. Oncology|July 26, 2011
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Yi-Long Wu, Gongyan Chen, et al.
The Lancet. Respiratory Medicine|November 24, 2024
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trialDongsheng Yue, Wenxiang Wang, Hongxu Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 21, 2020
Transcriptional and proteomic insights into the host response in fatal COVID-19 casesMeng Wu, Yaobing Chen, Han Xia, et al.
Plos Genetics|April 14, 2022
Abnormal global alternative RNA splicing in COVID-19 patientsChangli Wang, Lijun Chen, Yaobin Chen, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung CancerPatrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.
The Lancet. Respiratory Medicine|July 26, 2024
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 studyJin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, et al.
Pageof 25